September 20, 2024
Sept. 20, 2024 –
Zevra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has
approved MiplyffaTM (arimoclomol) capsules as an orally delivered treatment for Niemann-Pick disease type
C (NPC).
September 17, 2024
September 17, 2024 –
Bionpharma Inc. is voluntarily recalling (1) single Batch (2310083)
of Atovaquone Oral Suspension, 750mg per mL to the consumer level.
September 13, 2024
September 13, 2024 –
Genentech, announced the U.S. Food and Drug Administration (FDA) approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple
sclerosis (RMS)
September 13, 2024
September 13, 2024 –
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA)
approved Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds
September 12, 2024
September 12, 2024 –
Genentech announced the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs). The first and only PD-(L)1 inhibitor for subcutaneous (SC), under the skin injection for patients in the United States.
September 5, 2024
September 5, 2024 –
Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited announced the U.S. Food
and Drug Administration (FDA) approval of Boruzu, a new presentation of bortezomib for ready-to-use subcutaneous or intravenous (IV) administration.
August 2, 2024
Semaglutide Products Being Sold Online Without Prescriptions
By Elana Gotkine, HealthDay Reporter; Medically reviewed by Carmen Pope, BPharm.
August 2, 2024 - Semaglutide products are being sold online
By Elana Gotkine, HealthDay Reporter; Medically reviewed by Carmen Pope, BPharm.
August 2, 2024 - Semaglutide products are being sold online
August 1, 2024
August 01, 2024 -
Adaptimmune Therapeutics plc announced U.S. Food and Drug Administration (FDA)
accelerated approval of Tecelra